Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 9c; raises guidance

Amneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.19, $0.09 better than the analyst estimate of $0.10. Revenue for the quarter came in at $599 million versus the consensus estimate of $565.11 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 EPS of $0.45-$0.55, versus the consensus of $0.47. Amneal Pharmaceuticals sees FY2023 revenue of $2.3-2.4 billion, versus the consensus of $2.32 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04